PNC27 vs Thymogen
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: PNC-27, p53-HDM2 Disruptor Peptide
A chimeric anti-cancer peptide containing p53 residues 12-26 linked to a membrane-penetrating sequence. Selectively kills cancer cells by binding to HDM-2 expressed on cancer cell membranes, inducing membrane pore formation and necrosis while leaving normal cells unaffected.
Also: EW Dipeptide, Glu-Trp
A synthetic dipeptide (Glu-Trp) bioregulator derived from Thymalin, a thymus extract. One of Professor Khavinson's key immunomodulatory peptides, shown to stimulate T-lymphocyte development and normalize immune function. Has been used clinically in Russia for immune support.
Key Comparison Insights
- Both peptides belong to the Immune category, suggesting similar primary applications.
- Thymogen has stronger research evidence (Human Trials) compared to PNC27 (Animal Studies).
Detailed Comparison
| Attribute | PNC27 | Thymogen |
|---|---|---|
| Category | Immune | Immune |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | PNC27 contains two functional domains: residues 12-26 of the p53 HDM-2 binding domain on the N-terminus, and a membrane residency peptide (MRP/penetratin) on the C-terminus. Cancer cells uniquely express HDM-2 on their plasma membranes, while normal cells do not. PNC27 binds to this membrane-bound HDM-2, adopts an alpha-helical conformation similar to p53, and induces transmembrane pore formation. This causes extrusion of intracellular contents and rapid necrotic cell death. The peptide also enters cancer cells and disrupts mitochondrial membranes. Importantly, this mechanism is independent of intracellular p53 status - effective even in p53-null cancers. | Thymogen (alpha-glutamyl-tryptophan) stimulates cellular factors of immunogenesis, promotes proliferation and differentiation of T-lymphocyte precursors into mature immunocompetent cells. It normalizes the ratio of T-helpers to T-suppressors, increases cyclic adenosine monophosphate (cAMP) in T-lymphocyte precursors, and modulates immune cell maturation. Pharmacokinetic studies show rapid tissue uptake, particularly in liver, adrenals, kidney, lymph nodes, and thymus. |
| Common Dosing | No human dose - research compound only Not applicable - no human use | 1-2 capsules (10-20 mg) daily 1-2x daily, before meals |
| Administration | IV injection in animal studies - not for human use | Oral capsules, also available as nasal spray in some regions |
| Typical Duration | Research protocols only - no human use data | 30-day courses with 2-3 month breaks |
| Best Time to Take | Per research protocol | Morning, before meals |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Extensive in vitro research demonstrates PNC27 selectively kills multiple cancer cell types including breast (MCF-7), pancreatic (MIA-PaCa-2), cervical (HeLa, SW756), ovarian (OVCAR-3, OV-90), colon, lung, and leukemia (K562, U937, HL-60) cell lines. Effective concentration: 0.1-0.2 mg/mL kills most cancer cells. At 0.3 mg/mL, nearly 100% of K562 leukemia cells were killed. Studies confirm no toxicity to normal cells including fibroblasts and leukocytes. Mechanism involves membrane pore formation and necrosis (not apoptosis). Research published in PNAS and multiple peer-reviewed journals. | Originally isolated from Thymalin via reversed-phase HPLC, then synthesized. Clinical studies in Russia show immunomodulatory effects including normalization of T-cell subsets. Animal studies demonstrate geroprotective activity - Thymogen administration in rats led to increased survival and 1.5-fold decrease in tumor development. Has been used clinically for over 20 years as an immunomodulator. |
Frequently Asked Questions: PNC27 vs Thymogen
What is the difference between PNC27 and Thymogen?
PNC27 is a immune peptide that a chimeric anti-cancer peptide containing p53 residues 12-26 linked to a membrane-penetrating sequence. selectively kills cancer cells by binding to hdm-2 expressed on cancer cell membranes, inducing membrane pore formation and necrosis while leaving normal cells unaffected. Thymogen is a immune peptide that a synthetic dipeptide (glu-trp) bioregulator derived from thymalin, a thymus extract. one of professor khavinson's key immunomodulatory peptides, shown to stimulate t-lymphocyte development and normalize immune function. has been used clinically in russia for immune support. The main differences lie in their mechanisms of action and clinical applications.
Which is better, PNC27 or Thymogen?
Neither is universally "better" - the choice depends on your specific goals. PNC27 is typically used for immune purposes, while Thymogen is used for immune. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can PNC27 and Thymogen be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using PNC27 and Thymogen together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.
Related Comparisons
View Full Peptide Profiles
Educational Information Only
This comparison of PNC27 and Thymogen is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.